So L - Search Results

1

Translation control of the immune checkpoint in cancer and its therapeutic targeting.

Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, Stumpf CR, Xue L, Devericks E, So L, Nguyen HG, Griselin A, Gordan JD, Umetsu SE, Reich SH, Worland ST, Asthana S, Barna M, Webster KR, Cunningham JT, Ruggero D. Xu Y, et al. Among authors: so l. Nat Med. 2019 Feb;25(2):301-311. doi: 10.1038/s41591-018-0321-2. Epub 2019 Jan 14. Nat Med. 2019. PMID: 30643286 Free PMC article.

2

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. Janes MR, et al. Among authors: so l. Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091. Epub 2010 Jan 13. Nat Med. 2010. PMID: 20072130 Free PMC article.

3

The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes.

So L, Lee J, Palafox M, Mallya S, Woxland CG, Arguello M, Truitt ML, Sonenberg N, Ruggero D, Fruman DA. So L, et al. Sci Signal. 2016 May 31;9(430):ra57. doi: 10.1126/scisignal.aad8463. Sci Signal. 2016. PMID: 27245614 Free PMC article.

4

RNA-binding protein isoforms ZAP-S and ZAP-L have distinct antiviral and immune resolution functions.

Schwerk J, Soveg FW, Ryan AP, Thomas KR, Hatfield LD, Ozarkar S, Forero A, Kell AM, Roby JA, So L, Hyde JL, Gale M Jr, Daugherty MD, Savan R. Schwerk J, et al. Among authors: so l. Nat Immunol. 2019 Dec;20(12):1610-1620. doi: 10.1038/s41590-019-0527-6. Epub 2019 Nov 18. Nat Immunol. 2019. PMID: 31740798 Free PMC article.

5

Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.

So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, Fruman DA. So L, et al. J Biol Chem. 2013 Feb 22;288(8):5718-31. doi: 10.1074/jbc.M112.379446. Epub 2012 Dec 28. J Biol Chem. 2013. PMID: 23275335 Free PMC article.

6

Germline SAMD9L truncation variants trigger global translational repression.

Allenspach EJ, Soveg F, Finn LS, So L, Gorman JA, Rosen ABI, Skoda-Smith S, Wheeler MM, Barrow KA, Rich LM, Debley JS, Bamshad MJ, Nickerson DA, Savan R, Torgerson TR, Rawlings DJ. Allenspach EJ, et al. Among authors: so l. J Exp Med. 2021 May 3;218(5):e20201195. doi: 10.1084/jem.20201195. J Exp Med. 2021. PMID: 33724365 Free PMC article.

7

PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

So L, Fruman DA. So L, et al. Biochem J. 2012 Mar 15;442(3):465-81. doi: 10.1042/BJ20112092. Biochem J. 2012. PMID: 22364281 Free PMC article. Review.

8

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.

Mallya S, Fitch BA, Lee JS, So L, Janes MR, Fruman DA. Mallya S, et al. Among authors: so l. PLoS One. 2014 Feb 21;9(2):e88865. doi: 10.1371/journal.pone.0088865. eCollection 2014. PLoS One. 2014. PMID: 24586420 Free PMC article.

9

Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.

Yea SS, So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S, Fruman DA. Yea SS, et al. Among authors: so l. PLoS One. 2014 Jun 10;9(6):e99486. doi: 10.1371/journal.pone.0099486. eCollection 2014. PLoS One. 2014. PMID: 24915189 Free PMC article.

10

mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.

Limon JJ, So L, Jellbauer S, Chiu H, Corado J, Sykes SM, Raffatellu M, Fruman DA. Limon JJ, et al. Among authors: so l. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5076-85. doi: 10.1073/pnas.1407104111. Epub 2014 Nov 10. Proc Natl Acad Sci U S A. 2014. PMID: 25385646 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

185 results

Search Page